Key points are not available for this paper at this time.
The purpose of the study was to compare the effectiveness of PARP inhibitor maintenance therapy (mPARPi) in real-world practice by biomarker status BRCA1/2 alterations (BRCAalt) and a homologous recombination deficiency signature (HRDsig) in advanced ovarian cancer.
Building similarity graph...
Analyzing shared references across papers
Loading...
Debra L. Richardson
University of Oklahoma Health Sciences Center
Júlia C.F. Quintanilha
Boston University
Natalie Danziger
Boston Foundation
Clinical Cancer Research
Boston University
University of Oklahoma
University of Oklahoma Health Sciences Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Richardson et al. (Tue,) studied this question.
synapsesocial.com/papers/68e5e6efb6db64358757b878 — DOI: https://doi.org/10.1158/1078-0432.ccr-24-1225